GlassScriptPhysician profile
Pratima Aryal
NPI 1568053130
$2,616.10
in general payments reported to CMS, 2019-2025
16 companies · $697 in 2025
The $697 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2022: $262 · 2023: $813 · 2024: $565 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,061 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.98 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $737.23 | 2021-2024 | Lokelma, Farxiga |
| Amgen INC. | $519.85 | 2022-2025 | Krystexxa |
| Calliditas Therapeutics US INC. | $311.35 | 2023-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $280.78 | 2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $183.20 | 2021-2024 | |
| Daiichi Sankyo INC. | $125.00 | 2025 | Injectafer |
| Glaxosmithkline, LLC. | $119.51 | 2025 | Arexvy |
| Abbvie INC. | $71.56 | 2025 | |
| Alexion Pharmaceuticals, INC. | $61.16 | 2022-2023 | Soliris, Ultomiris |
| Akebia Therapeutics INC | $40.38 | 2022-2024 | Vafseo, Auryxia |
| Mallinckrodt Hospital Products INC. | $36.31 | 2024 | Acthar |
| Otsuka America Pharmaceutical, INC. | $32.47 | 2023-2024 | Jynarque |
| Vifor Pharma, INC. | $30.53 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $29.96 | 2024 | |
| Fresenius USA Marketing, INC. | $19.82 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pratima Aryal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.